CHD4 epigenetically coordinates genomic instability and immunosuppression to drive pan-cancer progression and confer HDAC inhibitor sensitivity. [PDF]
Fu G +7 more
europepmc +1 more source
The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications
1. This paper proposes the “oncobiome” as a unifying conceptual framework that integrates commensal, pathobiont, and tumor‐resident microbes into a coherent biological processor driving malignancy. 2. This study describes the dynamic shift from a homeostatic microbiome to a pathological oncobiome, detailing how diet, antibiotics, and environment ...
Xuan Zhang +6 more
wiley +1 more source
Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ<sub>1</sub>R Agonists/HDAC Inhibitor Dual-Acting Compounds. [PDF]
Fallica AN +16 more
europepmc +1 more source
ABSTRACT Purpose To evaluate lesion severity distribution in ischaemic brain lesions in spontaneously hypertensive rats (SHR) subjected to 90‐min transient middle cerebral artery occlusion (tMCAO), and to determine whether epigenetically based neuroprotection modifies lesion severity profiles using a voxel‐wise T2 distribution framework.
Andrea Díaz‐Pérez +3 more
wiley +1 more source
HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma. [PDF]
Li J +10 more
europepmc +1 more source
Clostridioides difficile toxins TcdA and TcdB enter intestinal epithelial cells (IECs) via specific receptors, disrupt tight‐junction integrity and activate PI3K/Akt/mTOR signalling, promoting inflammasome assembly and IL‐1β release. Toxin‐induced IEC apoptosis further weakens the epithelial barrier.
Sisi Zhang +7 more
wiley +1 more source
Epigenetic potentiation of 5-fluorouracil by HDAC inhibitor quisinostat enhances antitumor effects in colorectal cancer. [PDF]
Calibasi-Kocal G +4 more
europepmc +1 more source
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active. [PDF]
Sequera C +24 more
europepmc +1 more source
Organoids in pediatric cancer research
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [PDF]
Yang H +16 more
europepmc +1 more source

